Primary non-adherence to bisphosphonates in an integrated healthcare setting

Abstract

Summary

We estimated primary non-adherence to oral bisphosphonate medication and examined the factors associated with primary non-adherence. Nearly 30 % of women did not pick up their new bisphosphonate within 60 days. Identifying barriers and developing interventions that address patients’ needs and concerns at the time a new medication is prescribed are warranted.

Introduction

To estimate primary non-adherence to oral bisphosphonate medications using electronic medical record data in a large, integrated healthcare delivery system and to describe patient and prescribing provider factors associated with primary non-adherence.

Methods

Women aged 55 years and older enrolled in Kaiser Permanente Southern California (KPSC) with a new prescription for oral bisphosphonates between December 1, 2009 and March 31, 2011 were identified. Primary non-adherence was defined as failure to pick up the new prescription within 60 days of the order date. Multivariable logistic regression models were used to investigate patient factors (demographics, healthcare utilization, and health conditions) and prescribing provider characteristics (demographics, years in practice, and specialty) associated with primary non-adherence.

Results

We identified 8,454 eligible women with a new bisphosphonate order. Among these women, 2,497 (29.5 %) did not pick up their bisphosphonate prescription within 60 days of the order date. In multivariable analyses, older age and emergency department utilization were associated with increased odds of primary non-adherence while prescription medication use and hospitalizations were associated with lower odds of primary non-adherence. Prescribing providers practicing 10 or more years had lower odds of primary non-adherent patients compared with providers practicing less than 10 years. Internal medicine and rheumatology providers had lower odds of primary non-adherent patients than primary care providers.

Conclusion

This study found that nearly one in three women failed to pick up their new bisphosphonate prescription within 60 days. Identifying barriers and developing interventions aimed at reducing the number of primary non-adherent patients to bisphosphonate prescriptions are warranted.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

References

  1. 1.

    Beardon PH, McGilchrist MM, McKendrick AD, McDevitt DG, MacDonald TM (1993) Primary non-compliance with prescribed medication in primary care. Bmj 307:846–848

    PubMed  Article  CAS  Google Scholar 

  2. 2.

    Gadkari AS, McHorney CA (2010) Medication nonfulfillment rates and reasons: narrative systematic review. Curr Med Res Opin 26:683–705. doi:10.1185/03007990903550586

    PubMed  Article  Google Scholar 

  3. 3.

    Waalen J, Bruning AL, Peters MJ, Blau EM (2009) A telephone-based intervention for increasing the use of osteoporosis medication: a randomized controlled trial. Am J Manag Care 15:e60–70

    PubMed  Google Scholar 

  4. 4.

    Cook PF, Emiliozzi S, McCabe MM (2007) Telephone counseling to improve osteoporosis treatment adherence: an effectiveness study in community practice settings. Am J Med Qual 22:445–456. doi:10.1177/1062860607307990

    PubMed  Article  Google Scholar 

  5. 5.

    Greenwald B, Bardwell A, Malinak J, Rude R, Silverman SL, White-Greenwald M (2002) New bone density report format influences patient compliance in filling prescriptions for osteoporosis. Clin J Wom Health 2:13–18

    Article  Google Scholar 

  6. 6.

    Karter AJ, Parker MM, Moffet HH, Ahmed AT, Schmittdiel JA, Selby JV (2009) New prescription medication gaps: a comprehensive measure of adherence to new prescriptions. Health Serv Res 44:1640–1661. doi:10.1111/j.1475-6773.2009.00989.x

    PubMed  Article  Google Scholar 

  7. 7.

    Koebnick C, Langer-Gould AM, Gould MK, Chao CR, Iyer RL, Smith N, Chen W, Jacobsen SJ (2012) Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data. The Permanente Journal 16:37–41

    PubMed  Google Scholar 

  8. 8.

    Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:613–619

    PubMed  Article  CAS  Google Scholar 

  9. 9.

    Hosmer DW, Lemeshow S (1989) Applied logistic regression. John Wiley & Sons, New York

    Google Scholar 

  10. 10.

    Shin J, McCombs JS, Sanchez RJ, Udall M, Deminski MC, Cheetham TC (2012) Primary nonadherence to medications in an integrated healthcare setting. Am J Manag Care 18:426–434

    PubMed  Google Scholar 

  11. 11.

    Fischer MA, Choudhry NK, Brill G, Avorn J, Schneeweiss S, Hutchins D, Liberman JN, Brennan TA, Shrank WH (2011) Trouble getting started: predictors of primary medication nonadherence. Am J Med 124(1081):1089–1022. doi:10.1016/j.amjmed.2011.05.028

    Google Scholar 

  12. 12.

    Raebel MA, Ellis JL, Carroll NM, Bayliss EA, McGinnis B, Schroeder EB, Shetterly S, Xu S, Steiner JF (2012) Characteristics of patients with primary non-adherence to medications for hypertension, diabetes, and lipid disorders. J Gen Intern Med 27:57–64. doi:10.1007/s11606-011-1829-z

    PubMed  Article  Google Scholar 

  13. 13.

    Shah ND, Dunlay SM, Ting HH, Montori VM, Thomas RJ, Wagie AE, Roger VL (2009) Long-term medication adherence after myocardial infarction: experience of a community. Am J Med 122(961):967–913. doi:10.1016/j.amjmed.2008.12.021

    Google Scholar 

  14. 14.

    Shah NR, Hirsch AG, Zacker C, Taylor S, Wood GC, Stewart WF (2009) Factors associated with first-fill adherence rates for diabetic medications: a cohort study. J Gen Intern Med 24:233–237. doi:10.1007/s11606-008-0870-z

    PubMed  Article  Google Scholar 

  15. 15.

    Liberman JN, Hutchins DS, Popiel RG, Patel MH, Jan SA, Berger JE (2010) Determinants of primary nonadherence in asthama-controller and dyslipidemia pharmacotherapy. Am J Pharm Benefits 2:111–118

    Google Scholar 

  16. 16.

    Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X (2008) Interventions for enhancing medication adherence. Cochrane database of systematic reviews CD000011. doi:10.1002/14651858.CD000011.pub3

  17. 17.

    Derose SF, Green K, Marrett E, Cheetham TC, Chiu VY, Harrison TN, Reynolds K, Vansomphone SS, Scott RD (2012) Automated outreach to increase primary adherence to cholesterol-lowering medications. Arch Intern Med Published online: doi:10.1001/2013.jamainternmed.717

  18. 18.

    Gerend MA, Erchull MJ, Aiken LS, Maner JK (2006) Reasons and risk: factors underlying women's perceptions of susceptibility to osteoporosis. Maturitas 55:227–237. doi:10.1016/j.maturitas.2006.03.003

    PubMed  Article  Google Scholar 

  19. 19.

    Hsieh C, Novielli KD, Diamond JJ, Cheruva D (2001) Health beliefs and attitudes toward the prevention of osteoporosis in older women. Menopause 8:372–376

    PubMed  Article  CAS  Google Scholar 

  20. 20.

    McHorney CA, Spain CV (2011) Frequency of and reasons for medication non-fulfillment and non-persistence among American adults with chronic disease in 2008. Health Expect 14:307–320. doi:10.1111/j.1369-7625.2010.00619.x

    PubMed  Article  Google Scholar 

  21. 21.

    Reginster JY, Rabenda V (2006) Patient preference in the management of postmenopausal osteoporosis with bisphosphonates. Clin Interv Aging 1:415–423

    PubMed  Article  CAS  Google Scholar 

  22. 22.

    Scoville EA, de Leon P, Lovaton P, Shah ND, Pencille LJ, Montori VM (2011) Why do women reject bisphosphonates for osteoporosis? A videographic study. PLoS One 6:e18468. doi:10.1371/journal.pone.0018468

    PubMed  Article  CAS  Google Scholar 

  23. 23.

    Yood RA, Mazor KM, Andrade SE, Emani S, Chan W, Kahler KH (2008) Patient decision to initiate therapy for osteoporosis: the influence of knowledge and beliefs. J Gen Intern Med 23:1815–1821. doi:10.1007/s11606-008-0772-0

    PubMed  Article  Google Scholar 

  24. 24.

    Danese MD, Badamgarav E, Bauer DC (2009) Effect of adherence on lifetime fractures in osteoporotic women treated with daily and weekly bisphosphonates. J Bone Miner Res 24:1819–1826. doi:10.1359/jbmr.090506

    PubMed  Article  Google Scholar 

Download references

Acknowledgements

This study was funded by a contractual agreement between Kaiser Permanente Southern California and Amgen Inc., Thousand Oaks, CA.

Conflicts of interest

Dr. O’Malley is an employee of Amgen Inc. and owns stock in Amgen Inc. Drs. Muntner, Gold, Silverman, and Morisky have served as advisors for Amgen Inc. Drs. Muntner, Gold and Silverman have served as consultants for Amgen Inc. Drs. Reynolds and Muntner received research support from Amgen Inc. Dr. Silverman has served as an advisor for Lilly, Novartis and Pfizer/Wyeth. Dr. Silverman has served as a consultant for Genentech, Lilly, Novartis and Pfizer/Wyeth. Dr. Silverman has received research support from Lilly and Pfizer/Wyeth. This study was funded by a contractual agreement between Kaiser Permanente Southern California and Amgen Inc., Thousand Oaks, CA.

Author information

Affiliations

Authors

Corresponding author

Correspondence to K. Reynolds.

Appendix 1

Appendix 1

Table 4 International classification of diseases, 9th revision, Clinical modification (ICD-9-CM) codes

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Reynolds, K., Muntner, P., Cheetham, T.C. et al. Primary non-adherence to bisphosphonates in an integrated healthcare setting. Osteoporos Int 24, 2509–2517 (2013). https://doi.org/10.1007/s00198-013-2326-5

Download citation

Keywords

  • Adherence
  • Bisphosphonates
  • Postmenopausal osteoporosis
  • Primary non-adherence